Praxis Precision price target raised to $65 from $61 at Jefferies

Jefferies raised the firm’s price target on Praxis Precision (PRAX) to $65 from $61 and keeps a Buy rating on the shares after the company shared several epilepsy presentations at the IEC 2025 meeting. A “subtle new disclosure” is vormatrigine’s overall seizure-freedom rate of 14%, according to the analyst, who could envision “a meaningful +50-100% stock move” if its absolute efficacy is replicated in the subsequent placebo-controlled Phase 2/3 POWER1/2 datasets.